<DOC>
	<DOCNO>NCT00713544</DOCNO>
	<brief_summary>This study carry investigate AZD5672 effective treat Rheumatoid Arthritis ( RA ) compare placebo ( substance action ) etanercept ( medicine already available treat Rheumatoid Arthritis ) add treatment methotrexate . The purpose study also find dose AZD5672 effective treat RA find well body tolerate AZD5672 take 12 week .</brief_summary>
	<brief_title>A Proof Concept Dose Ranging Study Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>N- ( 1- ( 3- ( 3,5-difluorophenyl ) -3- ( 4-methanesulfonylphenyl ) propyl ) piperidin-4-yl ) -N-ethyl-2- ( 4-methanesulfonylphenyl ) acetamide</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis RA active disease define : ≥4 swollen joint ≥6 tender/painful joint , either ( blood test ) elevate erythrocyte sedimentation rate ( ESR ) Creactive protein ( CRP ) . At least one following : documented history positive rheumatoid factor ( blood test ) , current presence positive rheumatoid factor ( blood test ) , baseline radiographic erosion , presence serum anticyclic citrullinated peptide antibody ( bloo Be receive either : Oral ( tablet ) subcutaneous ( injection ) methotrexate least 6 month prior randomisation . Any inflammatory disease addition RA may interfere study ( e.g . polymyalgia rheumatica , giant cell arteritis , reactive arthritis , etc ) . Current chronic pain disorder include fibromyalgia chronic fatigue syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>AZD5672</keyword>
</DOC>